Hedge Fund Adds Jazz Drug To List Of AIA Review Targets

By Ryan Davis ( April 7, 2015, 3:13 PM EDT) -- An organization tied to hedge fund manager Kyle Bass on Monday asked the Patent Trial and Appeal Board to invalidate a patent covering Jazz Pharmaceuticals Inc. 's narcolepsy drug Xyrem, the latest in a series of America Invents Act review petitions that the group has filed challenging drug patents. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

This past year, a handful of attorneys secured billions of dollars in settlements and judgments for both classes and individual plaintiffs against massive companies and organizations like Facebook, Dell, the National Association of Realtors, Johnson & Johnson, UFC and Credit Suisse, earning them recognition as Law360's Titans of the Plaintiffs Bar for 2025.